Ardeparin - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (2)

Targets (2)Biointeractions (2)

Identification

Name

Ardeparin

Accession Number

DB00407 (APRD00803)

Type

Small Molecule

Groups

Approved, Withdrawn

Description

Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.

Structure

Synonyms

Not Available

External IDs

Not Available

Product Ingredients

Not Available

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Normiflo	Wyeth-Ayerst (United States)

Brand mixtures

Not Available

Categories

UNII

VL0L558GCB

CAS number

9005-49-6

Weight

Not Available

Chemical Formula

Not Available

InChI Key

Not Available

InChI

Not Available

IUPAC Name

Not Available

SMILES

Not Available

Pharmacology

Indication

For prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.

Structured Indications

Not Available

Pharmacodynamics

Ardeparin, an anticoagulant, is a fractionated heparin. It acts at multiple sites in the normal coagulation system to inhibit reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo.

Mechanism of action

Ardeparin binds to antithrombin III, accelerating its activity in inactivating factor Xa and thrombin, thereby inhibiting thrombosis. Ardeparin also binds to heparin cofactor II, inhibiting thrombin. Ardeparin does not effect prothrombin time (PT) assays and may prolong activated partial thromboplastin time (APTT). Ardeparin has double the anti-factor Xa activity versus anti-factor IIa activity, compared to unfractionated heparin which has approximately equal anti-factor Xa activity and anti-factor IIa activity.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Antithrombin-III	Protein	yes	potentiator	Human	P01008	details
Heparin cofactor 2	Protein	yes	agonist	Human	P05546	details

Absorption

Well absorbed following subcutaneous administration, with a mean bioavailability of 92% (based on anti-factor Xa activity).

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Liver and the reticulo-endothelial system are the sites of biotransformation.

Route of elimination

Not Available

Half life

Elimination half-life for anti-factor Xa activity averages 3.3 hours following a single intravenous dose, while elimination half-life for anti-factor IIa activity averages 1.2 hours following a single intravenous dose.

Clearance

Not Available

Toxicity

Symptoms of overdose may include excessive bleeding and bruising.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category	SMPDB ID
Enoxaparin Action Pathway	Drug action	SMP00272
Ardeparin Action Pathway	Drug action	SMP00275

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Abciximab	Abciximab may increase the anticoagulant activities of Ardeparin.	Approved
Aceclofenac	Aceclofenac may increase the anticoagulant activities of Ardeparin.	Approved
Acenocoumarol	Ardeparin may increase the anticoagulant activities of Acenocoumarol.	Approved
Acetylsalicylic acid	Acetylsalicylic acid may increase the anticoagulant activities of Ardeparin.	Approved, Vet Approved
Adapalene	Adapalene may increase the anticoagulant activities of Ardeparin.	Approved
Aliskiren	Ardeparin may increase the hyperkalemic activities of Aliskiren.	Approved, Investigational
Allylestrenol	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Allylestrenol.	Approved
Alprostadil	Alprostadil may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Alteplase	Alteplase may increase the anticoagulant activities of Ardeparin.	Approved
Altrenogest	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Altrenogest.	Vet Approved
ALX-0081	ALX-0081 may increase the anticoagulant activities of Ardeparin.	Investigational
Amiloride	Ardeparin may increase the hyperkalemic activities of Amiloride.	Approved
Aminosalicylic Acid	Aminosalicylic Acid may increase the anticoagulant activities of Ardeparin.	Approved
Anagrelide	Anagrelide may increase the anticoagulant activities of Ardeparin.	Approved
Ancrod	Ardeparin may increase the anticoagulant activities of Ancrod.	Investigational
Andrographolide	HMPL-004 may increase the anticoagulant activities of Ardeparin.	Investigational
Anisodamine	Anisodamine may increase the anticoagulant activities of Ardeparin.	Investigational
Anistreplase	Anistreplase may increase the anticoagulant activities of Ardeparin.	Approved
Antipyrine	Antipyrine may increase the anticoagulant activities of Ardeparin.	Approved
Antithrombin III human	Ardeparin may increase the anticoagulant activities of Antithrombin III human.	Approved
Apixaban	Apixaban may increase the anticoagulant activities of Ardeparin.	Approved
Apocynin	Acetovanillone may increase the anticoagulant activities of Ardeparin.	Investigational
Apremilast	Apremilast may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Aprotinin	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Aprotinin.	Approved, Withdrawn
Argatroban	Argatroban may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Astaxanthin	Astaxanthin may increase the anticoagulant activities of Ardeparin.	Investigational
Azapropazone	Azapropazone may increase the anticoagulant activities of Ardeparin.	Withdrawn
Azelastine	Azelastine may increase the anticoagulant activities of Ardeparin.	Approved
Azilsartan medoxomil	Ardeparin may increase the hyperkalemic activities of Azilsartan medoxomil.	Approved
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with Ardeparin.	Approved, Investigational
Batroxobin	Batroxobin may increase the anticoagulant activities of Ardeparin.	Experimental
Bazedoxifene	Bazedoxifene may decrease the anticoagulant activities of Ardeparin.	Approved, Investigational
Becaplermin	Becaplermin may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Bemiparin	Bemiparin may increase the anticoagulant activities of Ardeparin.	Approved
Benazepril	Ardeparin may increase the hyperkalemic activities of Benazepril.	Approved, Investigational
Benoxaprofen	Benoxaprofen may increase the anticoagulant activities of Ardeparin.	Withdrawn
Beraprost	Beraprost may increase the anticoagulant activities of Ardeparin.	Investigational
Betulinic Acid	Betulinic Acid may increase the anticoagulant activities of Ardeparin.	Investigational
Bivalirudin	Bivalirudin may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Bromfenac	Bromfenac may increase the anticoagulant activities of Ardeparin.	Approved
Bucillamine	Bucillamine may increase the anticoagulant activities of Ardeparin.	Investigational
Butylphthalide	Butylphthalide may increase the anticoagulant activities of Ardeparin.	Investigational
Canagliflozin	Ardeparin may increase the hyperkalemic activities of Canagliflozin.	Approved
Candesartan	Ardeparin may increase the hyperkalemic activities of Candesartan.	Approved
Candoxatril	Ardeparin may increase the hyperkalemic activities of Candoxatril.	Experimental
Cangrelor	Cangrelor may increase the anticoagulant activities of Ardeparin.	Approved
Captopril	Ardeparin may increase the hyperkalemic activities of Captopril.	Approved
Carprofen	Carprofen may increase the anticoagulant activities of Ardeparin.	Approved, Vet Approved, Withdrawn
Castanospermine	Castanospermine may increase the anticoagulant activities of Ardeparin.	Experimental
Celecoxib	Celecoxib may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Certoparin	Ardeparin may increase the anticoagulant activities of Certoparin.	Approved
Chloroquine	Chloroquine may increase the anticoagulant activities of Ardeparin.	Approved, Vet Approved
Chlorotrianisene	Chlorotrianisene may decrease the anticoagulant activities of Ardeparin.	Withdrawn
Choline magnesium trisalicylate	Trisalicylate-choline may increase the anticoagulant activities of Ardeparin.	Approved
Cilazapril	Ardeparin may increase the hyperkalemic activities of Cilazapril.	Approved
Cilostazol	Cilostazol may increase the anticoagulant activities of Ardeparin.	Approved
Citric Acid	Ardeparin may increase the anticoagulant activities of Citric Acid.	Nutraceutical, Vet Approved
Clonixin	Clonixin may increase the anticoagulant activities of Ardeparin.	Approved
Clopidogrel	Clopidogrel may increase the anticoagulant activities of Ardeparin.	Approved, Nutraceutical
Conjugated estrogens	Conjugated Equine Estrogens may decrease the anticoagulant activities of Ardeparin.	Approved
Curcumin	Curcumin may increase the anticoagulant activities of Ardeparin.	Investigational
D-Limonene	D-Limonene may increase the anticoagulant activities of Ardeparin.	Investigational
Dabigatran etexilate	Dabigatran etexilate may increase the anticoagulant activities of Ardeparin.	Approved
Dalteparin	Ardeparin may increase the anticoagulant activities of Dalteparin.	Approved
Danaparoid	Ardeparin may increase the anticoagulant activities of Danaparoid.	Approved, Withdrawn
Darexaban	Ardeparin may increase the anticoagulant activities of Ym150.	Investigational
Dasatinib	Dasatinib may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Deferasirox	The risk or severity of adverse effects can be increased when Ardeparin is combined with Deferasirox.	Approved, Investigational
Defibrotide	Defibrotide may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Deoxycholic Acid	The risk or severity of adverse effects can be increased when Ardeparin is combined with Deoxycholic Acid.	Approved
dersalazine	dersalazine may increase the anticoagulant activities of Ardeparin.	Investigational
Desirudin	Ardeparin may increase the anticoagulant activities of Desirudin.	Approved
Desmoteplase	Desmoteplase may increase the anticoagulant activities of Ardeparin.	Investigational
Desogestrel	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Desogestrel.	Approved
Dextran	Ardeparin may increase the anticoagulant activities of Dextran.	Approved, Vet Approved
Dextran 40	Ardeparin may increase the anticoagulant activities of Dextran 40.	Approved
Dextran 70	Ardeparin may increase the anticoagulant activities of Dextran 70.	Approved
Dextran 75	Ardeparin may increase the anticoagulant activities of Dextran 75.	Approved
Diclofenac	Diclofenac may increase the anticoagulant activities of Ardeparin.	Approved, Vet Approved
Dicoumarol	Dicoumarol may increase the anticoagulant activities of Ardeparin.	Approved
Dienestrol	Dienestrol may decrease the anticoagulant activities of Ardeparin.	Approved
Dienogest	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Dienogest.	Approved
Diethylstilbestrol	Diethylstilbestrol may decrease the anticoagulant activities of Ardeparin.	Approved
Diflunisal	Diflunisal may increase the anticoagulant activities of Ardeparin.	Approved
Dipyridamole	Dipyridamole may increase the anticoagulant activities of Ardeparin.	Approved
Ditazole	Ditazole may increase the anticoagulant activities of Ardeparin.	Approved, Withdrawn
Drospirenone	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Drospirenone.	Approved
Drotrecogin alfa	Drotrecogin alfa may increase the anticoagulant activities of Ardeparin.	Approved, Investigational, Withdrawn
Droxicam	Droxicam may increase the anticoagulant activities of Ardeparin.	Approved
Duvelisib	Duvelisib may increase the anticoagulant activities of Ardeparin.	Investigational
Dydrogesterone	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Dydrogesterone.	Approved, Withdrawn
E-6201	E6201 may increase the anticoagulant activities of Ardeparin.	Investigational
Ebselen	Ebselen may increase the anticoagulant activities of Ardeparin.	Investigational
Edetic Acid	Ardeparin may increase the anticoagulant activities of Edetic Acid.	Approved, Vet Approved
Edoxaban	Edoxaban may increase the anticoagulant activities of Ardeparin.	Approved
Enalapril	Ardeparin may increase the hyperkalemic activities of Enalapril.	Approved, Vet Approved
Enalaprilat	Ardeparin may increase the hyperkalemic activities of Enalaprilat.	Approved
Enoxaparin	Ardeparin may increase the anticoagulant activities of Enoxaparin.	Approved
Epinastine	Epinastine may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Epirizole	Epirizole may increase the anticoagulant activities of Ardeparin.	Approved
Eplerenone	Ardeparin may increase the hyperkalemic activities of Eplerenone.	Approved
eplivanserine	eplivanserine may increase the anticoagulant activities of Ardeparin.	Investigational
Epoprostenol	Epoprostenol may increase the anticoagulant activities of Ardeparin.	Approved
Eprosartan	Ardeparin may increase the hyperkalemic activities of Eprosartan.	Approved
Eptifibatide	Eptifibatide may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Equol	S Equol may decrease the anticoagulant activities of Ardeparin.	Investigational
Estradiol	Estradiol may decrease the anticoagulant activities of Ardeparin.	Approved, Investigational, Vet Approved
Estriol	Estriol may decrease the anticoagulant activities of Ardeparin.	Approved, Vet Approved
Estrone	Estrone may decrease the anticoagulant activities of Ardeparin.	Approved
Etanercept	Etanercept may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Ethinyl Estradiol	Ethinyl Estradiol may decrease the anticoagulant activities of Ardeparin.	Approved
Ethyl biscoumacetate	Ardeparin may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Ethynodiol diacetate	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Ethynodiol diacetate.	Approved
Etodolac	Etodolac may increase the anticoagulant activities of Ardeparin.	Approved, Investigational, Vet Approved
Etofenamate	Etofenamate may increase the anticoagulant activities of Ardeparin.	Approved
Etonogestrel	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Etonogestrel.	Approved, Investigational
Etoricoxib	Etoricoxib may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Evening primrose oil	Evening primrose oil may increase the anticoagulant activities of Ardeparin.	Approved
exisulind	exisulind may increase the anticoagulant activities of Ardeparin.	Investigational
Fenbufen	Fenbufen may increase the anticoagulant activities of Ardeparin.	Approved
Fenoprofen	Fenoprofen may increase the anticoagulant activities of Ardeparin.	Approved
Fibrinolysin	Plasmin may increase the anticoagulant activities of Ardeparin.	Investigational
Floctafenine	Floctafenine may increase the anticoagulant activities of Ardeparin.	Approved, Withdrawn
Fluindione	Ardeparin may increase the anticoagulant activities of Fluindione.	Investigational
Flunixin	Flunixin may increase the anticoagulant activities of Ardeparin.	Vet Approved
Flurbiprofen	Flurbiprofen may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Fondaparinux	Ardeparin may increase the anticoagulant activities of Fondaparinux.	Investigational
Fondaparinux sodium	Ardeparin may increase the anticoagulant activities of Fondaparinux sodium.	Approved, Investigational
Forasartan	Ardeparin may increase the hyperkalemic activities of Forasartan.	Experimental
Fosinopril	Ardeparin may increase the hyperkalemic activities of Fosinopril.	Approved
Gabexate	Ardeparin may increase the anticoagulant activities of Gabexate.	Investigational
Genistein	Genistein may decrease the anticoagulant activities of Ardeparin.	Investigational
Gestodene	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Gestodene.	Approved
Gestrinone	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Gestrinone.	Approved
Hemin	Hemin may increase the anticoagulant activities of Ardeparin.	Approved
Heparin	Ardeparin may increase the anticoagulant activities of Heparin.	Approved, Investigational
Hexestrol	Hexestrol may decrease the anticoagulant activities of Ardeparin.	Withdrawn
Higenamine	Higenamine may increase the anticoagulant activities of Ardeparin.	Investigational
Hydroxyprogesterone caproate	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Hydroxyprogesterone caproate.	Approved
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan.	Approved
Ibrutinib	The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ardeparin.	Approved
Ibudilast	Ibudilast may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Ibuprofen	Ibuprofen may increase the anticoagulant activities of Ardeparin.	Approved
Ibuproxam	Ibuproxam may increase the anticoagulant activities of Ardeparin.	Withdrawn
Icatibant	Icatibant may increase the anticoagulant activities of Ardeparin.	Approved
Icosapent ethyl	Icosapent ethyl may increase the anticoagulant activities of Ardeparin.	Approved, Nutraceutical
Idraparinux	Ardeparin may increase the anticoagulant activities of idraparinux.	Investigational
Ifenprodil	Ifenprodil may increase the anticoagulant activities of Ardeparin.	Approved, Withdrawn
Iloprost	Iloprost may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Imidapril	Ardeparin may increase the hyperkalemic activities of Imidapril.	Investigational
Indobufen	Indobufen may increase the anticoagulant activities of Ardeparin.	Investigational
Indomethacin	Indomethacin may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Indoprofen	Indoprofen may increase the anticoagulant activities of Ardeparin.	Withdrawn
Irbesartan	Ardeparin may increase the hyperkalemic activities of Irbesartan.	Approved, Investigational
Isoxicam	Isoxicam may increase the anticoagulant activities of Ardeparin.	Withdrawn
Kebuzone	Kebuzone may increase the anticoagulant activities of Ardeparin.	Experimental
Ketanserin	Ketanserin may increase the anticoagulant activities of Ardeparin.	Investigational
Ketoprofen	Ketoprofen may increase the anticoagulant activities of Ardeparin.	Approved, Vet Approved
Ketorolac	Ketorolac may increase the anticoagulant activities of Ardeparin.	Approved
Leflunomide	Leflunomide may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Lepirudin	Lepirudin may increase the anticoagulant activities of Ardeparin.	Approved
Levonorgestrel	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Levonorgestrel.	Approved, Investigational
Limaprost	The risk or severity of adverse effects can be increased when Limaprost is combined with Ardeparin.	Approved
Lisinopril	Ardeparin may increase the hyperkalemic activities of Lisinopril.	Approved, Investigational
Lisofylline	Lisofylline may increase the anticoagulant activities of Ardeparin.	Investigational
Lornoxicam	Lornoxicam may increase the anticoagulant activities of Ardeparin.	Approved
Losartan	Ardeparin may increase the hyperkalemic activities of Losartan.	Approved
Loxoprofen	Loxoprofen may increase the anticoagulant activities of Ardeparin.	Approved
Lumiracoxib	Lumiracoxib may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Lynestrenol	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Lynestrenol.	Investigational
Magnesium salicylate	Magnesium salicylate may increase the anticoagulant activities of Ardeparin.	Approved
Masoprocol	Masoprocol may increase the anticoagulant activities of Ardeparin.	Approved
Meclofenamic acid	Meclofenamic acid may increase the anticoagulant activities of Ardeparin.	Approved, Vet Approved
Medrogestone	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Medrogestone.	Approved
Medroxyprogesterone acetate	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Medroxyprogesterone acetate.	Approved, Investigational
Mefenamic acid	Mefenamic acid may increase the anticoagulant activities of Ardeparin.	Approved
Megestrol acetate	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Megestrol acetate.	Approved, Vet Approved
Meloxicam	Meloxicam may increase the anticoagulant activities of Ardeparin.	Approved, Vet Approved
Mesalazine	The risk or severity of adverse effects can be increased when Mesalazine is combined with Ardeparin.	Approved
Mestranol	Mestranol may decrease the anticoagulant activities of Ardeparin.	Approved
Metamizole	Metamizole may increase the anticoagulant activities of Ardeparin.	Withdrawn
Methallenestril	Methallenestril may decrease the anticoagulant activities of Ardeparin.	Experimental
Milrinone	Milrinone may increase the anticoagulant activities of Ardeparin.	Approved
Mizoribine	Mizoribine may increase the anticoagulant activities of Ardeparin.	Investigational
Moexipril	Ardeparin may increase the hyperkalemic activities of Moexipril.	Approved
Mycophenolate mofetil	Mycophenolate mofetil may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Mycophenolic acid	Mycophenolic acid may increase the anticoagulant activities of Ardeparin.	Approved
Nabumetone	Nabumetone may increase the anticoagulant activities of Ardeparin.	Approved
Nadroparin	Ardeparin may increase the anticoagulant activities of Nadroparin.	Approved
Nafamostat	Nafamostat may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Naftifine	Naftifine may increase the anticoagulant activities of Ardeparin.	Approved
Naftopidil	Naftopidil may increase the anticoagulant activities of Ardeparin.	Investigational
Naproxen	Naproxen may increase the anticoagulant activities of Ardeparin.	Approved, Vet Approved
Nepafenac	Nepafenac may increase the anticoagulant activities of Ardeparin.	Approved
Niflumic Acid	Niflumic Acid may increase the anticoagulant activities of Ardeparin.	Approved
Nimesulide	Nimesulide may increase the anticoagulant activities of Ardeparin.	Approved, Withdrawn
Nintedanib	The risk or severity of adverse effects can be increased when Ardeparin is combined with Nintedanib.	Approved
Nitroaspirin	Nitroaspirin may increase the anticoagulant activities of Ardeparin.	Investigational
Nomegestrol	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Nomegestrol.	Approved
Norethisterone	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Norethisterone.	Approved
Obinutuzumab	The risk or severity of adverse effects can be increased when Ardeparin is combined with Obinutuzumab.	Approved
Olmesartan	Ardeparin may increase the hyperkalemic activities of Olmesartan.	Approved, Investigational
Olopatadine	Olopatadine may increase the anticoagulant activities of Ardeparin.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with Ardeparin.	Approved
Omacetaxine mepesuccinate	The risk or severity of adverse effects can be increased when Ardeparin is combined with Omacetaxine mepesuccinate.	Approved
Omapatrilat	Ardeparin may increase the hyperkalemic activities of Omapatrilat.	Investigational
Omega-3 fatty acids	Omega-3 fatty acids may increase the anticoagulant activities of Ardeparin.	Approved, Nutraceutical
Orgotein	Orgotein may increase the anticoagulant activities of Ardeparin.	Vet Approved
Otamixaban	Ardeparin may increase the anticoagulant activities of Otamixaban.	Investigational
Oxaprozin	Oxaprozin may increase the anticoagulant activities of Ardeparin.	Approved
Oxyphenbutazone	Oxyphenbutazone may increase the anticoagulant activities of Ardeparin.	Withdrawn
Ozagrel	Kct 0809 may increase the anticoagulant activities of Ardeparin.	Investigational
Palifermin	The serum concentration of Palifermin can be increased when it is combined with Ardeparin.	Approved
Parecoxib	Parecoxib may increase the anticoagulant activities of Ardeparin.	Approved
Parnaparin	Parnaparin may increase the anticoagulant activities of Ardeparin.	Approved
Pentosan Polysulfate	Pentosan Polysulfate may increase the anticoagulant activities of Ardeparin.	Approved
Pentoxifylline	Pentoxifylline may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Perindopril	Ardeparin may increase the hyperkalemic activities of Perindopril.	Approved
Phenindione	Ardeparin may increase the anticoagulant activities of Phenindione.	Approved
Phenprocoumon	Ardeparin may increase the anticoagulant activities of Phenprocoumon.	Approved
Phenylbutazone	Phenylbutazone may increase the anticoagulant activities of Ardeparin.	Approved, Vet Approved
Pimecrolimus	Pimecrolimus may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Pirfenidone	Pirfenidone may increase the anticoagulant activities of Ardeparin.	Investigational
Piroxicam	Piroxicam may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Polyestradiol phosphate	Polyestradiol phosphate may decrease the anticoagulant activities of Ardeparin.	Approved
Prasugrel	Prasugrel may increase the anticoagulant activities of Ardeparin.	Approved
Progesterone	The therapeutic efficacy of Ardeparin can be decreased when used in combination with Progesterone.	Approved, Vet Approved
Promestriene	Promestriene may decrease the anticoagulant activities of Ardeparin.	Investigational
Propacetamol	Propacetamol may increase the anticoagulant activities of Ardeparin.	Approved
Protein C	Ardeparin may increase the anticoagulant activities of Protein C.	Approved
Protein S human	Ardeparin may increase the anticoagulant activities of Protein S human.	Approved
Protocatechualdehyde	Ardeparin may increase the anticoagulant activities of Protocatechualdehyde.	Approved
PTC299	PTC299 may increase the anticoagulant activities of Ardeparin.	Investigational
Quinapril	Ardeparin may increase the hyperkalemic activities of Quinapril.	Approved, Investigational
Quinestrol	Quinestrol may decrease the anticoagulant activities of Ardeparin.	Approved
Ramatroban	Ramatroban may increase the anticoagulant activities of Ardeparin.	Investigational
Ramipril	Ardeparin may increase the hyperkalemic activities of Ramipril.	Approved
Rescinnamine	Ardeparin may increase the hyperkalemic activities of Rescinnamine.	Approved
Resveratrol	Resveratrol may increase the anticoagulant activities of Ardeparin.	Experimental, Investigational
Reteplase	Reteplase may increase the anticoagulant activities of Ardeparin.	Approved
Reviparin	Ardeparin may increase the anticoagulant activities of Reviparin.	Approved
Ridogrel	Ridogrel may increase the anticoagulant activities of Ardeparin.	Approved
Rivaroxaban	Ardeparin may increase the anticoagulant activities of Rivaroxaban.	Approved
Rofecoxib	Rofecoxib may increase the anticoagulant activities of Ardeparin.	Investigational, Withdrawn
Rosiglitazone	Rosiglitazone may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Sacubitril	Ardeparin may increase the hyperkalemic activities of Sacubitril.	Approved
Salicylamide	Salicylamide may increase the anticoagulant activities of Ardeparin.	Approved
Salicylic acid	Salicylic acid may increase the anticoagulant activities of Ardeparin.	Approved, Vet Approved
Salsalate	Salsalate may increase the anticoagulant activities of Ardeparin.	Approved
Saprisartan	Ardeparin may increase the hyperkalemic activities of Saprisartan.	Experimental
Saralasin	Ardeparin may increase the hyperkalemic activities of Saralasin.	Investigational
Secoisolariciresinol	Secoisolariciresinol may decrease the anticoagulant activities of Ardeparin.	Investigational
Selexipag	Selexipag may increase the anticoagulant activities of Ardeparin.	Approved
Seratrodast	Seratrodast may increase the anticoagulant activities of Ardeparin.	Approved
Sevoflurane	Sevoflurane may increase the anticoagulant activities of Ardeparin.	Approved, Vet Approved
Spirapril	Ardeparin may increase the hyperkalemic activities of Spirapril.	Approved
Spironolactone	Ardeparin may increase the hyperkalemic activities of Spironolactone.	Approved
SRT501	SRT501 may increase the anticoagulant activities of Ardeparin.	Investigational
Streptokinase	Streptokinase may increase the anticoagulant activities of Ardeparin.	Approved
Sugammadex	Sugammadex may increase the anticoagulant activities of Ardeparin.	Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ardeparin.	Approved
Sulindac	Sulindac may increase the anticoagulant activities of Ardeparin.	Approved
Sulodexide	Ardeparin may increase the anticoagulant activities of Sulodexide.	Approved, Investigational
Suprofen	Suprofen may increase the anticoagulant activities of Ardeparin.	Approved, Withdrawn
Synthetic Conjugated Estrogens, A	Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Ardeparin.	Approved
Synthetic Conjugated Estrogens, B	Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ardeparin.	Approved
Tasosartan	Ardeparin may increase the hyperkalemic activities of Tasosartan.	Approved
Telmisartan	Ardeparin may increase the hyperkalemic activities of Telmisartan.	Approved, Investigational
Temocapril	Ardeparin may increase the hyperkalemic activities of Temocapril.	Experimental, Investigational
Tenecteplase	Tenecteplase may increase the anticoagulant activities of Ardeparin.	Approved
Tenoxicam	Tenoxicam may increase the anticoagulant activities of Ardeparin.	Approved
Tepoxalin	Tepoxalin may increase the anticoagulant activities of Ardeparin.	Vet Approved
Teriflunomide	Teriflunomide may increase the anticoagulant activities of Ardeparin.	Approved
Tesmilifene	Tesmilifene may increase the anticoagulant activities of Ardeparin.	Investigational
Tiaprofenic acid	Tiaprofenic acid may increase the anticoagulant activities of Ardeparin.	Approved
Tibolone	Tibolone may increase the anticoagulant activities of Ardeparin.	Approved
Ticagrelor	Ticagrelor may increase the anticoagulant activities of Ardeparin.	Approved
Ticlopidine	Ticlopidine may increase the anticoagulant activities of Ardeparin.	Approved
Tinoridine	Tinoridine may increase the anticoagulant activities of Ardeparin.	Investigational
Tinzaparin	Tinzaparin may increase the anticoagulant activities of Ardeparin.	Approved
Tipranavir	Tipranavir may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Tirofiban	Tirofiban may increase the anticoagulant activities of Ardeparin.	Approved
Tolfenamic Acid	Tolfenamic Acid may increase the anticoagulant activities of Ardeparin.	Approved
Tolmetin	Tolmetin may increase the anticoagulant activities of Ardeparin.	Approved
Tositumomab	The risk or severity of adverse effects can be increased when Ardeparin is combined with Tositumomab.	Approved
Trandolapril	Ardeparin may increase the hyperkalemic activities of Trandolapril.	Approved
Tranilast	Tranilast may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Trapidil	Trapidil may increase the anticoagulant activities of Ardeparin.	Approved
Treprostinil	Treprostinil may increase the anticoagulant activities of Ardeparin.	Approved, Investigational
Triamterene	Ardeparin may increase the hyperkalemic activities of Triamterene.	Approved
Triflusal	Triflusal may increase the anticoagulant activities of Ardeparin.	Approved
Urokinase	Urokinase may increase the anticoagulant activities of Ardeparin.	Approved, Investigational, Withdrawn
Valdecoxib	Valdecoxib may increase the anticoagulant activities of Ardeparin.	Investigational, Withdrawn
Valsartan	Ardeparin may increase the hyperkalemic activities of Valsartan.	Approved, Investigational
Vitamin E	Vitamin E may increase the anticoagulant activities of Ardeparin.	Approved, Nutraceutical, Vet Approved
Vorapaxar	The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ardeparin.	Approved
Warfarin	Ardeparin may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	Ardeparin may increase the anticoagulant activities of Ximelagatran.	Approved, Investigational, Withdrawn
Zaltoprofen	Zaltoprofen may increase the anticoagulant activities of Ardeparin.	Approved
Zeranol	Zeranol may decrease the anticoagulant activities of Ardeparin.	Vet Approved
Zileuton	Zileuton may increase the anticoagulant activities of Ardeparin.	Approved, Investigational, Withdrawn
Zomepirac	Zomepirac may increase the anticoagulant activities of Ardeparin.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

Not Available

External Links

Resource	Link
KEGG Drug	D02980
Therapeutic Targets Database	DAP000428
PharmGKB	PA164754878
Drugs.com	http://www.drugs.com/mtm/ardeparin.html
Wikipedia	Ardeparin

ATC Codes

Not Available

AHFS Codes

20:12.04.16
92:00.00

PDB Entries

1JVQ

FDA label

Not Available

MSDS

Download (65.5 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Basic Science	Altered Heparin Response / Cardiopulmonary Bypass	1
2	Completed	Prevention	Venous Thromboembolism	1
2	Terminated	Prevention	Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)	1
2	Withdrawn	Treatment	Diabetes, Diabetes Mellitus Type 1	1
3	Completed	Prevention	Cancers / Venous Thromboembolism	1
3	Completed	Prevention	Venous Thromboembolism	5
3	Completed	Treatment	Deep Vein Thrombosis (DVT)	1
3	Recruiting	Prevention	Catheter-Related Infections / Kidney Failure,Chronic	1
3	Terminated	Prevention	Venous Thromboembolism	1
4	Recruiting	Treatment	Infertilities	1
Not Available	Recruiting	Not Available	Intra Operative Bleeding, Blood Salvage	1

Pharmacoeconomics

Manufacturers

Wyeth ayerst laboratories

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Soluble	Not Available

Predicted Properties

Not Available

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key

Taxonomy

Classification

Not classified

Targets

Details

1. Antithrombin-III

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: potentiator

General Function:: Serine-type endopeptidase inhibitor activity
Specific Function:: Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.
Gene Name:: SERPINC1
Uniprot ID:: P01008
Uniprot Name:: Antithrombin-III
Molecular Weight:: 52601.935 Da

References

Mousa SA: The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev. 2002 Fall;20(3):199-216. [PubMed:12397367 ]
Lin P, Sinha U, Betz A: Antithrombin binding of low molecular weight heparins and inhibition of factor Xa. Biochim Biophys Acta. 2001 Apr 3;1526(1):105-13. [PubMed:11287128 ]
Shaughnessy SG, Young E, Deschamps P, Hirsh J: The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood. 1995 Aug 15;86(4):1368-73. [PubMed:7632944 ]

Details

2. Heparin cofactor 2

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Serine-type endopeptidase inhibitor activity
Specific Function:: Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner.Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.
Gene Name:: SERPIND1
Uniprot ID:: P05546
Uniprot Name:: Heparin cofactor 2
Molecular Weight:: 57070.16 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Mousa SA: The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev. 2002 Fall;20(3):199-216. [PubMed:12397367 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Drug created on June 13, 2005 07:24 / Updated on June 21, 2017 11:43